Syndax Pharmaceuticals SNDX Business Segments — Personnel Cost And Other General Expenses

Similar metrics at other companies

DNLITherapeutics Segment — Personnel related general and administrative expenses

$22.56M+20.4%

DNLITherapeutics Segment — Other general and administrative expenses

$10.95M+3.1%

VCYTBiopharmaceutical and other revenue — Other cost

$8K-99.2%

LHBiopharma Laboratory Services — Other Cost and Expense, Operating

$89.7M-0.3%

ANABBiopharma Company — General And Administrative Expense

$18.86M+92.1%

DNLITherapeutics Segment — General and administration

$33.51M+14.2%

Questions, answered.

What is Syndax Pharmaceuticals's business segments — personnel cost and other general expenses?

Syndax Pharmaceuticals (SNDX) reported business segments — personnel cost and other general expenses of $16.7M in Q1 2026.

How has Syndax Pharmaceuticals's business segments — personnel cost and other general expenses changed year-over-year?

Syndax Pharmaceuticals's business segments — personnel cost and other general expenses decreased by 12.5% year-over-year, from $19.08M to $16.7M.

What is the long-term trend for Syndax Pharmaceuticals's business segments — personnel cost and other general expenses?

Over 3 years (2022 to 2025), Syndax Pharmaceuticals's business segments — personnel cost and other general expenses has grown at a 84.8% compound annual growth rate (CAGR), from $11.3M to $71.27M.

What does business segments — personnel cost and other general expenses mean?

This captures the administrative and general support costs associated with the personnel managing the cancer therapeutics business unit. It covers overhead functions that support the segment's operations beyond direct R&D or sales activities. Tracking this helps investors understand the operational leverage and administrative burden of the business segment.